Easywell Biomedicals, Inc.

As of June 30, 2026, Easywell Biomedicals, Inc. carries a market capitalization of 3.89B, placing it among publicly traded companies globally. Its enterprise value stands at 3.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Easywell Biomedicals, Inc. has 124.69M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.84, and the price-to-book ratio stands at 5.48.

As of June 30, 2026, Easywell Biomedicals, Inc. trades at an EV/EBITDA multiple of 38.37 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.81B versus a market cap of 3.89B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Easywell Biomedicals, Inc. maintains a current ratio of 2.68, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 53.43, indicating elevated leverage, while an interest coverage ratio of 5.15 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Easywell Biomedicals, Inc. posted a negative return on equity (ROE) of -2.30, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.25, reflecting losses generated across the asset base. The company generates approximately 14.03M in revenue per employee across its workforce of 57.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.59 indicates how many times Easywell Biomedicals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Easywell Biomedicals, Inc. recorded 78,000.00 in income tax expense. The company reported a pretax loss of -14.43M and -15.64M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Easywell Biomedicals, Inc.'s stock has declined approximately 37.47% over the past 52 weeks. The 50-day moving average sits at 29.28, while the 200-day moving average is 33.27.

Over the twelve months ended June 30, 2026, Easywell Biomedicals, Inc. generated 799.94M in revenue and converted that into -15.64M in net income, yielding earnings per share of -0.12. EBITDA reached 99.20M, while operating income came in at -5.23M.

As of June 30, 2026, Easywell Biomedicals, Inc. holds 484.70M in cash and equivalents against 386.54M in total debt, resulting in a net debt position of -305.82M. Total book value stands at 709.28M, with working capital of 442.53M providing operational flexibility.

Easywell Biomedicals, Inc. produced 182.34M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -13.78M in capital expenditures, free cash flow totaled 168.56M - equivalent to 1.36 per share.

Over the twelve months ended June 30, 2026, Easywell Biomedicals, Inc. posted a gross margin of 46.87, reflecting its pricing power and cost economics. The operating margin of -0.65 and net profit margin of -1.96 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 4.35, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.25, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Easywell Biomedicals, Inc. shareholders.

Easywell Biomedicals, Inc.'s most recent stock split took place on January 10, 2024 with a 91:92 split ratio.

As of June 30, 2026, Easywell Biomedicals, Inc. has an Altman Z-Score of 4.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.